Stocklytics Platform
Asset logo for symbol BIO
Bio-Rad Laboratories
BIO51
$224.09arrow_drop_down1.63%-$3.71
Asset logo for symbol BIO
BIO51

$224.09

arrow_drop_down1.63%
Key Stats
Open$223.85
Prev. Close$227.14
EPS-65.36
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range220.73
227.25
52 Week Range220.73
428.05
Ratios
EPS-65.36
Fundamentals
Payout Ratio-
Industry average yield2.89%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

BIO-
US Healthcare Sector-
US Market-
warning

BIO / Market

BIO lose to the US Market which returned 0.03% over the last twenty four hours.
warning

BIO / Healthcare Sector

BIO lose to the US Healthcare sector which returned 2.60% over the last twenty four hours.

Bio-Rad Laboratories (BIO) Statistics

Bio-Rad Laboratories Inc (BIO) is a leading global provider of life science research and clinical diagnostic products. The company's stock statistics reflect its strong position in the market. With a market capitalization of $16.5 billion, BIO is considered a large-cap stock. Its average daily trading volume is around 300,000 shares, indicating a healthy level of investor interest. BIO's stock price has been on an upward trajectory in recent years, reaching an all-time high of $695.23 per share. This positive performance is a testament to the company's solid fundamentals and growth potential.
BIO's valuation metrics further highlight its attractiveness as an investment. The company has a price-to-earnings ratio of 58.41, indicating that investors are willing to pay a premium for its earnings. Its price-to-sales ratio is 5.93, suggesting that investors are also optimistic about BIO's revenue growth. Additionally, BIO's enterprise value-to-EBITDA ratio is 24.75, indicating that it is generating strong operating cash flow relative to its enterprise value. These valuation metrics underscore the company's strong financial position and potential for future growth.
add Bio-Rad Laboratories  to watchlist

Keep an eye on Bio-Rad Laboratories

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Bio-Rad Laboratories (BIO) stock's performance compared to its sector and the market over the past year?

Over the past year, Bio-Rad Laboratories (BIO) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 15.12%, Bio-Rad Laboratories has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 23.87%, it has fallen short of the market average. This comparison highlights Bio-Rad Laboratories 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Bio-Rad Laboratories (BIO) stock?

The PE ratio for Bio-Rad Laboratories (BIO) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Bio-Rad Laboratories (BIO) stock?

The Earnings Per Share (EPS) for Bio-Rad Laboratories (BIO), calculated on a diluted basis, is -$65.36. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Bio-Rad Laboratories (BIO) stock?

The operating margin for Bio-Rad Laboratories (BIO) is 8.68%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Bio-Rad Laboratories (BIO) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Bio-Rad Laboratories (BIO) is $504.2M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Bio-Rad Laboratories (BIO) have?

Bio-Rad Laboratories (BIO) has a total debt of $1.37B. The net debt, which accounts for cash and cash equivalents against the total debt, is -$486.9M.

Take Your Investments to a Whole New Level